Our top pick for
CyrusOne Inc is a reit-specialty business based in the US. CyrusOne shares (CONE) are listed on the NASDAQ and all prices are listed in US Dollars. CyrusOne employs 456 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$90.36|
|52-week range||$68.07 - $90.36|
|50-day moving average||$89.93|
|200-day moving average||$82.69|
|Wall St. target price||$89.65|
|Dividend yield||$2.06 (2.29%)|
|Earnings per share (TTM)||$0.20|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2022-06-24)||N/A|
|1 month (2022-06-01)||N/A|
|3 months (2022-04-01)||N/A|
|6 months (2022-01-05)||0.94%|
|1 year (2021-07-02)||26.91%|
|2 years (2020-07-02)||19.54%|
|3 years (2019-07-05)||50.40%|
|5 years (2017-07-05)||65.04%|
Valuing CyrusOne stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of CyrusOne's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
CyrusOne's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 452x. In other words, CyrusOne shares trade at around 452x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
CyrusOne's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $557.8 million.
The EBITDA is a measure of a CyrusOne's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1.2 billion|
|Operating margin TTM||4.86%|
|Gross profit TTM||$674.6 million|
|Return on assets TTM||0.51%|
|Return on equity TTM||0.92%|
|Market capitalisation||$11.9 billion|
TTM: trailing 12 months
Dividend payout ratio: 66.13% of net profits
Recently CyrusOne has paid out, on average, around 66.13% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.29% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), CyrusOne shareholders could enjoy a 2.29% return on their shares, in the form of dividend payments. In CyrusOne's case, that would currently equate to about $2.06 per share.
CyrusOne's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
CyrusOne's most recent dividend payout was on 7 April 2022. The latest dividend was paid out to all shareholders who bought their shares by 24 March 2022 (the "ex-dividend date").
Over the last 12 months, CyrusOne's shares have ranged in value from as little as $68.0725 up to $90.36. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CyrusOne's is 0.3844. This would suggest that CyrusOne's shares are less volatile than average (for this exchange).
CyrusOne (NASDAQ: CONE) is a premier global REIT specializing in design, construction and operation of more than 50 high-performance data centers worldwide. The Company provides mission-critical facilities that ensure the continued operation of IT infrastructure for approximately 1,000 customers, including approximately 200 Fortune 1000 companies. A leader in hybrid-cloud and multi-cloud deployments, CyrusOne offers colocation, hyperscale, and build-to-suit environments that help customers enhance the strategic connection of their essential data infrastructure and support achievement of sustainability goals. CyrusOne data centers offer world-class flexibility, enabling clients to modernize, simplify, and rapidly respond to changing demand. Combining exceptional financial strength with a broad global footprint, CyrusOne provides customers with long-term stability and strategic advantage at scale. .
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.